<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081808</url>
  </required_header>
  <id_info>
    <org_study_id>RWH 111-32</org_study_id>
    <nct_id>NCT01081808</nct_id>
  </id_info>
  <brief_title>Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roger Williams Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roger Williams Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving autologous lymphocytes that have been treated in the laboratory with&#xD;
      antibodies may stimulate the immune system to kill tumor cells. Aldesleukin may stimulate the&#xD;
      lymphocytes to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the&#xD;
      number of immune cells found in bone marrow or peripheral blood. Giving laboratory-treated&#xD;
      autologous lymphocytes together with aldesleukin and GM-CSF may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of laboratory-treated&#xD;
      autologous lymphocytes when given together with aldesleukin and GM-CSF in treating patients&#xD;
      with recurrent, refractory, or metastatic advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
      Determine the safety and maximum tolerated dose of EGFRBi-armed autologous activated T-cells&#xD;
      (ATC) when administered in combination with low-dose aldesleukin and sargramostim (GM-CSF) in&#xD;
      patients with recurrent, refractory, or extensive (metastatic) advanced solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
      Assess clinical outcome based on tumor responses, overall survival, and progression-free&#xD;
      survival.&#xD;
&#xD;
      Monitor changes in sera concentrations of the tumor-associated biomarkers respective of the&#xD;
      primary neoplasm (i.e. carcinoembryonic antigen(CEA); prostate specific antigen (PSA);&#xD;
      Her2/neu (HER2); etc.) in association with EGFRBi-armed ATC administration throughout the&#xD;
      study and at time points thereafter.&#xD;
&#xD;
      Monitor patient sera for human anti-mouse antibodies (HAMA).&#xD;
&#xD;
      Evaluate immune response, which may reflect immune augmentation in response to EGFRBi-armed&#xD;
      ATC infusions, in peripheral blood mononuclear cell (PBMC) samples as well as purified immune&#xD;
      cell populations.&#xD;
&#xD;
      Investigate proliferation in response to ex vivo stimulation with tumor-specific antigens,&#xD;
      sera cytokine profiles (Th1 vs Th2), cytotoxicity of patient PBMC, and interferon gamma&#xD;
      ELISPOTS as a surrogate marker for assessing generation of EGFR-specific cytotoxic&#xD;
      T-lymphocytes (CTL).&#xD;
&#xD;
      OUTLINE: Peripheral blood mononuclear cells (PBMCs) are collected by 1 or 2 leukaphereses for&#xD;
      the generation of activated T cells (ATCs). The PBMCs are activated with OKT3 (anti-CD3) and&#xD;
      expanded in aldesleukin for up to 14 days. The ATCs are then armed with EGFRBi.&#xD;
&#xD;
      Patients receive EGFRBi-armed autologous ATCs IV over 30-60 minutes twice weekly for 4 weeks&#xD;
      (a total of 8 infusions) in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients also receive low-dose aldesleukin subcutaneously (SC) once daily and sargramostim&#xD;
      (GM-CSF) SC twice weekly beginning 3 days before the first ATC infusion and continuing for 1&#xD;
      week after the last ATC infusion.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
&#xD;
      NOTE: For the purpose of determining safety and maximum tolerated dose of EGFRBi-armed ATC,&#xD;
      patients enrolled at each dose level from this study will be combined with patients enrolled&#xD;
      at each dose level in RWH 349-32 (NCT00569296): A phase I study of Anti-CD3 x Cetuximab-Armed&#xD;
      Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung&#xD;
      Cancer (NSCLC) to count toward each dose level cohort. A total of three patients enrolled&#xD;
      form either of the two trials will be treated at each dose level, but at least one NSCLC&#xD;
      patient representative from protocol 349-32 will be enrolled and evaluated at each dose&#xD;
      level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding ended&#xD;
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of EGFRBi-armed autologous activated T-cells</measure>
    <time_frame>5 week regimen with 2 month follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine potential side effects of treating patients with Armed Activated T Cells (ATC)</measure>
    <time_frame>5 week regimen with 2 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of immunologic changes by evaluation of cytokine profiles obtained before and after stimulation with OKT3 in vitro</measure>
    <time_frame>5 week regimen with 2 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of immunologic changes by evaluation of phenotypes of peripheral blood mononuclear cells before and after immunotherapy</measure>
    <time_frame>5 week regimen with 2 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 week regimen wtih 2 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 week regimen with 2 month follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of immunologic changes by evaluation of peripheral blood lymphocytes</measure>
    <time_frame>5 week regimen with 2 month follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Neoplasms</condition>
  <condition>Tumors</condition>
  <condition>Solid Tumors</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Armed Activated T Cells</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EGFRBi-armed autologous activated T cells</intervention_name>
    <description>EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.</description>
    <arm_group_label>Armed Activated T Cells</arm_group_label>
    <other_name>ATC</other_name>
    <other_name>IL-2</other_name>
    <other_name>GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor type (ex. Head and Neck Squamous&#xD;
             Cell Carcinoma, Colorectal, Pancreatic, Gastric, Esophageal, Renal, Prostate, Breast&#xD;
             and Ovarian cancers, etc.); high risk, recurrent, refractory, or metastatic disease&#xD;
             after ≥ 1 prior first-line regimen (chemotherapy or radiotherapy)&#xD;
&#xD;
          -  Documented EGFR-positive disease (any expression level) by immunohistochemistry (IHC)&#xD;
&#xD;
          -  No clinical evidence of active brain metastases; patients with brain metastases are&#xD;
             eligible provided they have received definitive radiotherapy or chemotherapy and/or&#xD;
             have undergone surgical resection for brain metastases&#xD;
&#xD;
          -  No prior hematological malignancy&#xD;
&#xD;
          -  Karnofsky performance status (PS) 60-100% OR RCOG PS 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use contraception&#xD;
&#xD;
          -  Granulocytes ≥ 1,000/mm3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 8g/dL&#xD;
&#xD;
          -  BUN ≤ 2.0 times normal&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times normal (with or without liver metastases)&#xD;
&#xD;
          -  Hepatitis B surface antigen and HIV negative&#xD;
&#xD;
          -  LVEF ≥ 45% at rest by MUGA&#xD;
&#xD;
          -  No evidence of depressed left ventricular function&#xD;
&#xD;
          -  No other malignancy, except for the following:&#xD;
&#xD;
          -  History of curatively treated in situ squamous cell carcinoma or basal cell carinoma&#xD;
             of the skin&#xD;
&#xD;
          -  History of other curatively treated malignancy (except those with a hematologic&#xD;
             origin) for with the patient has remained in complete remission &gt; 5 years after&#xD;
             completing therapy (as documented by history, physical exams, tumor markers, and&#xD;
             radiology scanning)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Serious medical or psychiatric illness that would preclude giving informed consent or&#xD;
             receiving intensive treatment&#xD;
&#xD;
          -  Recent myocardial infarction (within the past year)&#xD;
&#xD;
          -  Current angina/coronary symptoms requiring medications&#xD;
&#xD;
          -  Clinical evidence of congestive heart failure requiring medical management&#xD;
             (irrespective of MUGA results)&#xD;
&#xD;
          -  Systolic blood pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 m Hg; patients with&#xD;
             elevated BP must have it controlled by anti-hypertensive medications for at least 7&#xD;
             days prior to the infusion&#xD;
&#xD;
          -  Clinical evidence of active brain metastases&#xD;
&#xD;
        Prior/Concurrent Therapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior cetuximab or small molecule EGFR-inhibitors including,&#xD;
             but not limited to, gefitinib or erlotinib hydrochloride&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No concurrent steroids except for treatment or adrenal failure, septic shock, or&#xD;
             pulmonary toxicity or hormones for non-disease-related conditions(e.g., insulin for&#xD;
             diabetes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abby Maizel, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Roger William Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roger Willaims Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PhaseI</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>biomarkers</keyword>
  <keyword>T cell</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Epidermal Growth Factor Receptor</keyword>
  <keyword>Aldesleukin</keyword>
  <keyword>Lymphocytes</keyword>
  <keyword>Autologous</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Refractory</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Anti-Retroviral Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

